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KEY FINDINGS  25 
•  LbK39 is an excellent antigen for diagnosing canine visceral leishmaniosis; 26 
• The sensitivity of the method was 100%;  27 
• The specificity was 96.1%.  28 
 29 
SUMMARY 30 
Visceral leishmaniosis is one of the most important zoonotic diseases on the planet and dogs are 31 
the main reservoir of canine visceral leishmaniosis (CVL) in endemic areas. They play an important role in 32 
human infection because in dogs the disease appears long time after infection, and they can move 33 
uncontrollably, contributing to disperse the parasite. To take the decision to treat the animals or for 34 
euthanasia, in an elimination program, in order to reduce the parasitic load, it is necessary to diagnose 35 
correctly, having more effective tools. Our group has developed a new recombinant antigen-based kinesin-36 
related gene of Leishmania braziliensis (Lbk39), which shows 59% amino acid identity to the L. infantum 37 
homologue. The Lbk39 gene was synthesized, inserted into the pLEXSY-sat2 vector and transfected into 38 
L. tarentolae cells by electroporation. The recombinant protein was secreted in the culture with a C-terminal 39 
histidine marker, purified, generating a product at 337.68 μg / mL. A total of 152 sera from dog’s endemic 40 
and non-endemic areas were used, being 78 positives and 75 negatives. The antigen Lbk39 showed 100% 41 
sensitivity and 96.1% specificity. We compared this antigen with other antigens such as total extract of the 42 
parasite, TRDPP, and our data indicate that Lbk39 has potential application in the diagnosis of CVL through 43 
antibody detection. 44 
 45 
Keywords: Recombinant antigen; ELISA; visceral leishmaniosis; dogs; Canis familiaris 46 
  47 
Introduction  48 
Canine visceral leishmaniosis (CVL) is a neglected tropical disease caused by protozoa of the 49 
genus Leishmania Ross, 1903, which affects dogs from all continents, except Oceania (Colwell et al. 2011, 50 
Dantas-Torres et al. 2012, Otranto et al. 2019). More than 20 Leishmania species are known to exist, and 51 
in dogs Leishmania infantum is the etiological agent of CVL. Visceral leishmaniosis (VL) also affects 52 
humans in Europe, the Middle East, South Asia, Africa, and in Central and South America, where 53 
transmission may be anthroponotic, but where dogs with CVL can also act as reservoir hosts for human 54 
infection, transmitted by the bites of sand fly vectors (Chappuis et al. 2007, WHO, 2010). In the Americas, 55 
human VL is mainly if not exclusively zoonotic and found in at least 12 countries, however, 90% of the 56 
cases are reported in Brazil, causing approximately 4,200-6,300 infections per year, with a 7% mortality 57 
rate (Romero et al. 2010, Alvar et al. 2012; WHO, 2017). The increasing spread of L. infantum into urban 58 
areas in the Americas is of great concern, and is associated with migration, population growth and poor 59 
living conditions (Werneck et al. 2008, Romero et al. 2010, Harhay et al. 2011). CVL is a multisystemic 60 
disease with clinical signs that may be apparent, such as dermatitis, lymphadenomegaly, general muscular 61 
atrophy, and renal disease (Baneth et al. 2008). However, control programmes for both the disease and 62 
infection are essential, because many dogs remain asymptomatic, which makes it difficult to diagnose 63 
infection and control transmission to humans (Gavgani et al. 2002; WHO, 2010). Current methods to 64 
prevent the spread of CVL include the use of topical insecticides on dogs and canine vaccination, which 65 
provides only a certain level of protection for dogs (Solano-Gallego et al. 2009; Sousa-Paula et al. 2019). 66 
In addition, many countries have also used euthanasia of seropositive dogs (Dantas-Torres et al. 2012, 67 
BRASIL, 2014). However, scientific studies have not yet shown that this euthanasia strategy decreases the 68 
infection rate of VL (Romero et al. 2010, Sosa-Paula et al. 2019; Dantas-Torres et al. 2019). Moreover, the 69 
method is not well-received by the population for ethical reasons (Costa et al. 2011, Pereira-da-Silva et al. 70 
2017). The treatment of CVL-positive dogs is permitted in some countries, however, euthanasia may still 71 
be the only option for owners who cannot afford to have their dogs treated. Therefore, the development of 72 
more precise diagnostic methods for both rapid treatment of humans and control of CVL in dogs is urgently 73 
required (Foglia Manzillo 2013, Fonseca et al. 2014, Coelho et al. 2016). 74 
For accurate diagnosis of CVL several approaches are available. The parasitological method of 75 
biopsy followed by detecting the amastigote forms of L. infantum by microscopy is still considered the gold 76 
standard (BRASIL, 2014). However, it is an invasive method and there are complications with its use due 77 
to the need for a trained professional capable of recognising the parasites. Culture methods to supplement 78 
microscopy give improved sensitivity but are also highly susceptible to contamination (Boelaert et al. 2007, 79 
Goto et al. 2010, de Vries et al. 2015). Polymerase chain reaction (PCR) methods to detect Leishmania 80 
DNA show variable sensitivity, even though it is a species-specific method (Gomes et al. 2017, Rampazzo 81 
et al. 2017). Various serological methods can be used including enzyme-linked immunosorbent assay 82 
(ELISA), indirect fluorescence antibody test (IFAT), direct agglutination test, Western blot and 83 
immunochromatographic tests to detect specific antibodies present in serum samples; however, these can 84 
present problems in sensitivity and specificity (Georgiadou et al. 2015, Magalhães et al. 2017). Nonetheless, 85 
such serological techniques can be highly efficient in the detection of VL infection in humans and dogs. To 86 
standardise and optimise their use many recombinant proteins have been studied in recent years with the 87 
aim of increasing the sensitivity and specificity of such tests (Wolf et al. 2014, Celeste et al. 2004, Mniouil 88 
et al. 2018).  89 
In Brazil the Ministry of Health has determined that the lateral flow strip test Dual-Path Platform 90 
assay (TR-DPP® LVC) produced by Bio-Manguinhos/Fiocruz, Brazil (BRASIL 2014) should be used for 91 
serological screening of dogs, followed by an ELISA test (EIE-LVC) for confirmation of L. infantum 92 
infection (Grimaldi et al. 2012, Faria et al. 2015). Some purified recombinant antigens, such as the rK39 93 
antigen, of various Leishmania species have been produced and used in serological assays of VL (Badaró 94 
et al. 1996). Even though the TR-DPP® test uses a combination of recombinant proteins (rK26 and rK39)  95 
which should improve sensitivity (Bhatia et al. 1999; Pattabhi et al. 2010), it can perform with low 96 
sensitivity, which compromises the efficacy of the diagnosis of infection in Brazil (Grimaldi et al. 2012, 97 
De Santis et al. 2013). Further, the crude parasite extract used in the EIE-LVC test has also shown false 98 
positive results due to cross-reactivity with other pathogens, particularly Trypanosoma cruzi, in North, 99 
Central and South America (Ferreira et al. 2007, Solano-Gallego et al. 2009). Cross-reactions are less likely 100 
to occur when using recombinant proteins in ELISA, such as rA2, rK9, rK26 and rK39 (Solano-Gallego et 101 
al. 2009). Considering the need for new antigens for improved serodiagnosis of CVL that show both high 102 
specificity and sensibility, and no cross-reaction with other diseases, we undertook this study, in which we 103 
investigated the use of the recently described Lbk39 recombinant protein (Souza et al. 2019) as an antigen 104 
in CVL diagnosis by the ELISA method.  105 
 106 
 107 
Materials and Methods 108 
 109 
Production of Lbk39 recombinant protein 110 
 Lbk39 recombinant protein was produced essentially as previously described (Souza et al. 2019). 111 
Briefly, the Lbk39 fragment of a kinesin-related gene of L. braziliensis is composed of 843 base pairs and 112 
encodes repetitive immunological amino acids. The protein is related to the kinesin-related gene of L. 113 
infantum (Burns et al. 1993), which has 6.5 repetitions of 39 amino acids. The synthetic gene Lbk39 was 114 
cloned with a 6xHis-tag in the recombinant vector pLEXSY-sat2 and inserted into the eukaryotic host L. 115 
tarentolae (Souza et al. 2019). 116 
 An aliquot of transfected L. tarentolae was thawed and placed in 100 mL of culture medium. As 117 
soon as the cultures became slightly turbid after 24 h, the specific Streptothricin-class of aminoglycoside 118 
antibiotic Nourseothricin (LEXSY NTC, Jena Bioscience) for the pLEXSY-sat2 vector was added, and the 119 
culture maintained under the same conditions by subpassage every four days. After that the pre-inoculum 120 
was inoculated in BHI medium (2 L) supplemented with 2 mL of porcine hemin (Jena Bisocience), 5 mL 121 
of penicillin and streptomycin (Pen-Strep, Jena Bioscience) and 1 mL of NTC antibiotic (Jena Bioscience) 122 
and incubated at 26°C in the dark under aerated conditions. The culture was then centrifuged at 5000 g, 123 
4°C, for 10 min, the supernatant medium removed and stored frozen at -80°C. 124 
Lbk39 recombinant protein (250 mL) was purified from the supernatant medium using HisTrap 125 
HP column chromatography (GE HealthCare) by loading the thawed culture medium supernatant into the 126 
column and eluting the purified protein, according to the manufacturer’s instructions. To remove salts and 127 
imidazole present in the purified protein, dialysis in PBS buffer 7.2 was performed at 4°C, once overnight, 128 
and twice for 2 h. The purified product (25 mL) was lyophilised to concentrate the Lbk39 recombinant 129 
protein. To determine the concentration of Lbk39 recombinant protein, the Micro BCA™ Protein Assay 130 
Kit (Thermo Fischer Scientific) was used, following the manufacturer’s protocol. To verify that the protein 131 
was indeed purified, 15% SDS-PAGE SDS-polyacrylamide gel electrophoresis was performed on 132 
recombinant Lbk39 produced after the protein purification process, dialysis and lyophilisation (for details 133 
see De Souza et al. 2019). The gel was stained with nitrate silver (Fig. 1).  134 
 135 
Collection and sample processing 136 
For this study, 152 canine serum samples were used to evaluate the diagnostic potential of Lbk39 in the 137 
main part of the study. Of these, 73 sera were from healthy animals from a non-endemic area of Brazil 138 
(Araucária, Parana), which can be assumed to be almost exclusively negative for CVL, with possible 139 
exception of rare imported cases. For the positive sera, we used dog samples from the region of the outbreak 140 
Foz do Iguaçu (for more details, see Thomaz Soccol et al. 2017). To assess the clinical diagnosis of CLV, 141 
clinical signals were recorded in an epidemiological questionnaire. Owned dogs were examined by 142 
veterinarians for clinical signs of the disease and each dog was given an individual data file including 143 
identification, traits, behaviour, migration history and health issues. Signals investigated were weight loss, 144 
adenomegaly, alopecia, skin lesions, mucosal lesions, hipkeratosis, and muscle atrophy. Blood samples 145 
were collected by venipuncture of the jugular vein, transferred to 10 mL polypropylene tubes and processed 146 
3-4 hours after collection. In the laboratory, the blood was centrifuged at 1000 xg for 5-10 min and the sera 147 
were separated and stored at -20°C until analysed by serological methods. The TR-DPP (Bio-Manguinhos, 148 
Fiocruz, Brazil) as recommendation from the Brazilian Ministry of Health and used according to 149 
manufacturer’s instructions. The indirect ELISA using total extract of L. infantum was performed as 150 
described by Maziero et al. (2014).  Each sample was tested in triplicate intra- and inter-plate. Three positive 151 
and negative dog sera were included in each plate as controls, when testing individual sera. 152 
Dogs that tested seropositive were examined by puncture of popliteal lymph nodes. The collected 153 
material was used for culture in NNN media and polymerase chain reaction (PCR) specific for Leishmania. 154 
DNA extraction was performed using the Wizard® Genomic DNA Purification Kit in accordance with the 155 
manufacturer's recommendations. Cytochrome B1/B2 was used as an internal control to verify DNA 156 
amplification (Oshaghi et al. 2006). The PCR was performed using Internal Transcribed Spacer (ITS) 157 
primers (Schonian et al. 2003). The positive PCR products were sequenced. The sequencing was performed 158 
commercially by Macrogen Inc. (Seoul, South Korea). The 79 positives sera were from dogs in an area 159 
highly endemic for CVL (Foz do Iguaçu), and included 52 sera from clinical cases for CVL and 27 sera 160 
from no clinical dogs. In addition to these sera, to evaluate potential cross-reaction, 23 sera were used from 161 
dogs positive for Toxoplasma gondii infection. 162 
 163 
Ethics Statement 164 
For collection of dog’s samples all procedures were carried out in strict compliance with the rules 165 
defined by the National Council for the Control of Animal Experiments (CONCEA), and every effort was 166 
made to minimize suffering. The work was approved by the Ethics Committee of the Federal University of 167 
Paraná, under protocol no. 044/2014.  The owners have signed a consent form for the use of the samples. 168 
 169 
Lbk39 antigen - Enzyme-linked immunosorbent assay (ELISA) standardization 170 
 The ELISA test was developed and standardised by analysing results using antigens at different 171 
concentrations (0.031, 0.062, 0.125, 0.250, 0.500 and 1,000 µg/well), two serum dilutions (1:100 and 1:200) 172 
and various dilutions of HRP-conjugated secondary antibodies (1:3500, 1:5000, 1:7500 and 1:10000). The 173 
Lbk39 antigen was diluted in carbonate-bicarbonate buffer, pH 9.6, and polystyrene microtiter plates (96-174 
well EIA/RIA 12x8 well plates, Costar, USA) were coated with 100 µL/well of dilutions at all of the 175 
concentrations of antigens given above, and incubated overnight at 4°C. The next day, the plates were 176 
washed with 200 μL/well of washing solution (0.9% NaCl + 0.05% Tween 20), twice. Next, the wells were 177 
blocked with 120 µL of blocking solution composed of PBS + 0.1% casein at 37°C, for 1 h, and were then 178 
washed again, twice, with 200 μL/well of washing solution. After these steps, the serum samples were 179 
added and incubated at 37°C, for 1 h. The plates were then washed with 200 µL/well of washing solution 180 
four times. 100 µL of various dilutions of a polyclonal goat anti-dog IgG HRP (2 mg/mL) conjugate was 181 
plated at the concentrations given above at 37°C, for 1 h. Lastly, the reaction was developed by adding 100 182 
μL/well of a solution prepared by combining 10.0 mL of citrate buffer (4.5% Na2PO4 + 3.25% citric acid + 183 
distilled water, pH 5.0), 2 mg of o-phenylenediamine dihydrochloride (2 mg/tablet, Sigma, USA) and 2 µL 184 
of 30% H2O2, and incubating at room temperature for 30 min, avoiding light. The reaction was stopped by 185 
adding 20 µL/well of 1:20 H2SO4 solution. The plates were read in a PowerWave HT reader (BioTek) at 186 
492 nm and the values were expressed in absorbance. The cut-off was calculated from the mean value of 187 
the negative controls.  188 
 189 
Tests used for comparison with the Lbk 39 antigen 190 
To confirm the CVL status of dogs within the study the following three standard tests were used: 191 
parasitological diagnosis by culture of aspirates in Novy, Neal and Nicolle medium; serological diagnosis 192 
using the TR-DPP test; and serological diagnosis using an ELISA test using total crude extract of L. 193 
infantum promastigotes (equivalent to the EIE-LVC test). These results were compared with those obtained 194 
using ELISA with Lbk39 recombinant protein.  195 
Parasitological diagnosis by culture was done as recommended by Szargiki et al. (2009). In brief, bone 196 
marrow aspirate, lymph node aspirate or the leukocyte layer of dogs were inoculated in Neal, Novy and 197 
Nicole (NNN) culture medium with 0.9% saline solution with weekly sub-passage, for four weeks at 24ºC. 198 
The cultures were inspected every week for the presence of promastigotes. Positive cultures were identified 199 
as described by Thomaz Soccol et al. (2017) and all found to be L. infantum. 200 
 201 
Statistical analysis 202 
  The receiver operating characteristics (ROC) curve, sensitivity, specificity analysis and 203 
comparison between tests were analysed by MedCalc, version 18.9 (R Core Team, 2018), Graphpad prism 204 




Antigen production 209 
A pre-inoculum culture was produced in 100 mL of medium, followed by the inoculation into one 210 
litre of supplemented BHI medium for antigen production.  After four days the culture was centrifuged and 211 
separated into pellet and supernatant medium. The total protein concentration in the supernatant medium 212 
was 8,286.52 μg/mL. The supernatant medium was processed in 250 mL aliquots, and each was used for 213 
protein purification using chromatography by loading the culture medium on to a 1 mL HisTrap HP column 214 
(GE HealthCare), according to the manufacturer’s instructions.  After purification by elution from the 215 
column, dialysis was performed to remove salts and imidazole from the eluate. Finally, the product was 216 
lyophilised and the Lkb39 protein was resuspended in ultrapure water and concentration was determined to 217 
be 337.68 μg/mL measured by the Micro BCA™ method.  218 
 219 
Enzyme-linked immunosorbent assay (ELISA) 220 
The ELISA test was evaluated for its ability to determine the level of anti-Leishmania antibodies 221 
in dog sera from L. infantum-infected and non-infected animals using as antigen the recombinant protein 222 
Lbk39. The ELISA was optimised by performing tests at six antigen concentrations and was able to 223 
differentiate sera positive for CVL from negative sera. The concentration chosen as standard was 125 µg 224 
protein per well, since this produced the best response for the most reasonable cost. In the assays performed, 225 
we observed a 34-fold increase in the absorbance values of positive controls compared with negative 226 
controls.  227 
The cut-off value was calculated using ROC curve analysis. For serum dilution optimisation, no 228 
significant differences were observed amongst the dilutions tested, thus the 200-fold dilution was chosen 229 
because it uses a small quantity of serum and the background was lower. The dilution of the goat anti-dog 230 
IgG HRP conjugate that gave the best results was 1: 7500, so this was selected for use as standard. To 231 
determine the cut-off level of the reaction of positive and negative sera, the mean and standard deviation 232 
absorbances of the canine samples negative for CVL (73 sera samples) were determined. The absorbance 233 
cut-off was set at 0.156. 234 
After standardisation, we used the optimised ELISA with Lbk39 antigen to analyse all 152 canine 235 
sera in the study. From this analysis, of the 79 dog sera from the CVL endemic region of Foz do Iguaçu, 76 236 
were positive and 3 were negative in the Lbk39 ELISA assay. Of these 3 negative animals, two were in the 237 
group with no clinical signs, one of these was negative in all other assays used and one was positive with 238 
the TR-DPP assay. The negative result from the dog with clinical signs was positive with the crude antigen 239 
ELISA and TR-DPP assays. Therefore, we conclude that two of these negative results from Foz do Iguaçu 240 
were false negatives and one was a true negative. All the dog sera from Araucária showed negative results 241 
with the Lbk39 assay. The ROC curve analysis of absorbance distribution against the Lbk39 antigen for 242 
various groups studied (all positives from any assay, dogs with clinical signs, dogs without clinical signs) 243 
is shown in Figure 2. The difference in canine samples was significant between these groups (P< 0.001) 244 
and accurate.  The positive group (78 samples) presented good accuracy (AUC, 0.998), similar to the no 245 
clinical signs group (AUC, 0.998), while the animals with clinical signs presented higher accuracy (AUC, 246 
0.999).  247 
Culture is used as a standard test for CVL diagnosis, because although it may sometimes lack 248 
sensitivity, it has very high specificity, as when it is positive it definitively means that the dog has the 249 
parasite. Therefore, we evaluated the subset of 56 dogs that presented with a positive culture. Table 2 shows 250 
the results for sensitivity and specificity of the Lbk39 assay with these sera, also subdivided into those with 251 
clinical signs or no clinical signs. As shown, the Lbk39 assay performed with very high sensitivity and 252 
specific against this subset of dog sera. ROC curve analysis of the absorbance distribution for the Lbk39 253 
ELISA against the positive culture subset confirmed that the test worked very well (P< 0.001) and was 254 
accurate (Fig. 3). The total positives group presented the same accuracy (AUC, 0.999) as the clinical signs 255 
subgroup (AUC, 0.999), while the no clinical signs subgroup presented with slightly lower accuracy (AUC, 256 
0.997).  257 
Analysis of the distribution of ELISA readings from the Lbk39 assay in various subgroups of dog 258 
sera is shown in Figure 4. Comparisons are shown between negative controls, positives, those positives 259 
with clinical signs and those positives with no clinical signs, either for all sera (Fig. 4a) or for the subset of 260 
Lbk39 ELISA positives with positive culture (Fig. 4b). All groups and subgroups of positives were 261 
significantly different to the negative controls. When the analysis was confined to sera from dogs that also 262 
had a positive culture, as expected the discrimination was greater (Fig. 4b).  263 
 264 
Comparison of Lbk39 with other diagnostic tests  265 
In addition to evaluating the performance of the Lbk39 ELISA against clinical and parasitological 266 
diagnostic tests, we also we compared our standardised assay with other commonly used serological tests, 267 
ELISA with a crude antigen preparation and the TR-DPP assay. For these comparisons we considered a 268 
true positive to be any animal that was positive in any of the assays used. This comparison showed that the 269 
Lbk39 assay outperformed all the other tests in terms of sensitivity (Table 3). The Lbk39 assay also 270 
performed well in terms of specificity (96.1%), with either TR-DPP being slightly better (97.2%). As 271 
mentioned previously, culture is highly specific, but this has a relative poor sensitivity (77%). 272 
Operationally, dogs with CVL are first identified by clinical signs and then the TR-DPP test is applied, 273 
sometimes this being the only testing performed. Therefore, we divided the positive group into cases with 274 
clinical signs and without clinical signs and evaluated the sensitivity and specificity of Lbk39 comparing 275 
with the TR-DPP assay (Table 4). When the individual groups were analysed, this showed that the group 276 
of sera from dogs with clinical signs were detected with similar and high sensitivity and specificity for both 277 
tests, the TR-DPP being slightly more specific. However, in dogs without clinical signs the Lbk39 ELISA 278 
was significantly more sensitive, and slightly less specific than TR-DPP. 279 
 280 
Cross-reaction with Lbk39 281 
To check for potential cross-reactivity of the Lbk39 antigen with another intracellular parasite, we 282 
performed ELISA with Lbk39 against sera from toxoplasmosis-positive canine samples. No cross-reaction 283 
was observed (Fig.5). 284 
 285 
DISCUSSION 286 
Leishmania braziliensis is endemic in the study area and, L. infantum has been recognized since 287 
2012 (Dias et al., 2013; Thomaz Soccol et al., 2017), therefore to work with specific species of CVL dogs 288 
were subjected to clinical evaluation and identification of the parasite present in the popliteal ganglion. In 289 
endemic areas of L. braziliensis, diseased dogs generally have typical well-limited ulcerated lesions with 290 
raised edges. The main locations of ulcers are in the scrotal sac and on top of the ears (Dantas-Torres et al. 291 
2010). Dogs with CVL generally exhibit lymphadenomegaly, exfoliative dermatitis and weight loss as the 292 
most relevant signals on which veterinarians have based their suspicion of infection (Gálvez et al. 2011). 293 
In the present study, no animals showed specific signs of CL. In addition, all animals that tested 294 
serologically positive on initial testing the parasite isolated was identified as L. infantum.  295 
Accurate diagnosis of CVL is important in efforts to interrupt the life cycle of the parasite and 296 
prevent the spread of the disease in endemic areas (Fraga et al. 2014; Singh et al. 2015). The recombinant 297 
protein Lbk39 previously described by our group (de Souza et al. 2019) has been validated here for use in 298 
the diagnosis of CVL. Antigen production was not performed in E. coli, but in L. tarentolae. As the desired 299 
recombinant antigen is derived from a Leishmania species, the use of this system maximizes the probability 300 
of successful expression. The antigenic protein produced by heterologous expression of specific 301 
Leishmania epitopes in a prokaryotic system such as E. coli is inexpensive to culture and allows rapid 302 
processing of the target recombinant protein. However, this system has drawbacks, e.g. it requires post-303 
translational eukaryotic activity, may have high levels of unfolded proteins, resulting in reduced efficacy. 304 
In addition, the ideal culture temperature for E. coli may reduce recombinant protein yield and increase 305 
protein degradation (Khow and Suntrarachun. 2012). Leishmania tarentolae, which is a non-mammalian 306 
pathogenic species, has been explored as a general eukaryotic host with the aim of developing a platform 307 
within it that allows high levels of expression of complex eukaryotic proteins and has the ability to produce 308 
proteins with appropriate post-translational processing (Basile and Peticca, 2009). This type of host is also 309 
easy to manipulate and has an inexpensive culture medium with an average doubling time of 6-8 hours. 310 
The recombinant protein, produced by our group, has been tested for LC and VLH with excellent results 311 
(de Souza et al. 2019).  312 
Here, we used this protein for CVL and an ELISA test format was chosen because it is a preferred 313 
choice for serodiagnosis screening of the disease in the laboratory, being generally more reliable and 314 
sensitive than other laboratory tests (Srividya et al. 2012; Abass et al. 2015). The Lbk39 antigen showed 315 
higher sensitivity (100%) when compared with TR-DPP (93.8%), ELISA using as antigen the parasite total 316 
extract (98.1%), or parasite culture (77%). The specificity was similar to that of TR-DPP (96.1 and 97.2%, 317 
respectively), and better than crude parasite extract (86.9%). These findings showed that Lbk39 has the 318 
highest probability of a true positive result in the presence of the disease, and it has the lowest probability 319 
of a false negative result in the absence of the disease compared with other tests. To increase specificity 320 
and minimise the possibility of a false positive, we used a cut-off value based on the standard deviation of 321 
the results of negative controls from healthy dogs, and as a consequence the Lbk39 assay did not produce 322 
many false negative results. However, when we evaluated only the canine samples from dogs with a positive 323 
culture with or without clinical signs, we observed that our protein showed 100% sensitivity in both groups, 324 
and a small variation in specificity between the groups with clinical signs (98.7%) and without clinical 325 
signs (96.0%). While evaluating TR-DPP, we observed that the group with clinical signs showed higher 326 
sensitivity (98%) than the group without (88%). As for the specificity, in positive group, dogs with either 327 
no clinical signs or clinical signs for TR-DPP presented 100%, whereas our protein presented specificity 328 
from 96.1 to 98.7%. 329 
In the last 10 years several CVL diagnostic methods have been used. Their specificity and 330 
sensitivity can vary. For example the specificity of molecular tests varies from 95 to 100%, where 331 
conventional PCR (cPCR) has a sensitivity of 89% to 100% in polysymptomatic dogs (Lachaud et al. 2002; 332 
Manna et al. 2004; Carson et al. 2010). However, sensitivity decreases when the method is applied to 333 
asymptomatic dogs (Francino et al. 2006; Gao et al. 2015). Currently, quantitative PCR (qPCR) is 334 
considered the most reliable test because it has a sensitivity of 91% compared to cPCR (72%), ITS-1 PCR 335 
(54%), and PCR hybridization (61%) (Carson et al. 2010). The molecular test with loop-mediated 336 
amplification (LAMP) is capable to amplify DNA in constant temperature in blood of VL patients. It has a 337 
sensitivities and specificities of 90.7 to 96.4% and 98.5 to 100%, respectively. In China, the LAMP 338 
identified 61%-infected dogs, however, not amplify strains from other countries (Gao et al. 2015). The 339 
direct agglutination test (DAT) present sensitivities of 91 to 100% and specificities of 72 to 100% but yet 340 
subjective reading of end-point titles leads to interrupt server discrepancy (Adams et al.  2012; Oliveira et 341 
al. 2016). Although some serological tests for canine leishmanosis have high specificity and sensitivity, the 342 
presence of cross-reactivity remains controversial. The immunofluorescence antibody test is reference 343 
qualitative in CVL diagnosis (Paltrinieri et al. 2016), with sensitivity and specificity close to 100%, in 344 
symptomatic animals, though show some limitations as, cross-reactivity with trypanosomes pathogens 345 
(Solano-Gallego et al. 2014; Paltrinieri et al. 2016) and the significantly lower sensitivity in identifying 346 
asymptomatic dogs compared with ELISA (Mettler et al. 2005).   347 
The main sera used to verify cross-reactivity against the antigen of choice would be T. cruzi, 348 
Babesia canis, Dirofilaria immitis and T. gondii, however, in the present study, it was possible to test only 349 
the cross-reactivity against T. gondii serum available for use. In previous studies, cross reactivity between 350 
Leishmania species and T. gondii were tested by ELISA and IFAT (Boelaert et al. 2007; Ferreira et al. 351 
2007) and showed no cross-reactivity. However, other studies showed that half of dogs (5/10; 50%) with 352 
anti-T. gondii antibodies were erroneously considered serologically positive for visceral leishmaniasis 353 
(Távora et al. 2007). In evaluating the validity of diagnostic methods, such problems need to be taken fully 354 
into account in order to obtain reliable and accurate results.  The use of Lbk39 against dog sera from animals 355 
positive for T. gondii no showed no cross-reactivity, such that the results of these samples were very similar 356 
to negative CVL samples.  357 
Our data corroborate the work of Grimaldi et al. (2012), who showed that TR-DPP has good 358 
detection rates in symptomatic dogs (98%) when screening is performed in endemic areas, but detection is 359 
lower when performed on asymptomatic dogs (47%). In the same way, Laurenti et al. (2014) showed that 360 
TR-DPP is better at detecting symptomatic dogs (92.1%) than asymptomatic dogs (89.4%). The Lbk39 361 
antigen studied here presented excellent accuracy (0.998), showing a potential for use in diagnostic tests. 362 
The literature shows that the best antigens are composed of repetitive motifs, which are present in 363 
various organisms and are characterised by the presence of two or more copies of amino acid sequences. 364 
This is because these sequences stimulate B cells by binding to these repetitive antigens, independent of T 365 
lymphocyte stimulation (Rosati et al. 2003; Goto et al. 2008, 2010; Valiente-Gabioud et al. 2011). Thus, 366 
proteins that exhibit these characteristics are strong candidates for use as diagnostic and vaccine targets. 367 
Our results corroborate these previously published data in which repetitive proteins showed higher 368 
sensitivity than non-repetitive proteins with canine samples. An important difference in sensitivity has also 369 
been shown between human and dog sera (Vos et al. 2000; Laurenti et al. 2014). This may be related to 370 
host-parasite reactions in relation to the recognition and presentation of the antigens studied to the immune 371 
system or to the different survival mechanisms of the parasite in different hosts (Laurenti et al. 2014). In 372 
fact, the test results may vary depending on the stage of the disease during which serum was collected 373 
(Mettler et al. 2005). This indicates that dogs with clinical signs show a better response to the serological 374 
tests, as also observed here. However, the recombinant protein evaluated here showed a CI min of 88.9 and 375 
a CI max of 99.2% for specificity, when the dogs showed no clinical signs and positive culture. When 376 
testing all the positive samples, the recombinant protein Lbk39 presented a sensitivity of 100% and a 377 
specificity of 96.1%, which is effective for diagnosing L. infantum in infected dogs. In addition, the protein 378 
was produced on a scale of two litres and purified without affecting its functionality. Therefore, this protein 379 
is a good candidate for use as a diagnostic target.  380 
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  662 
Table 1. Characteristics and location of canine blood samples. 663 
Characteristics Locality N Diagnostic tests 
Dogs with clinical signs* 
from endemic area 
Foz do Iguaçu - PR 52 Culture, ELISA, TR-DPP 
No clinical signs from 
endemic area 
Foz do Iguaçu - PR 27 Culture, ELISA, TR-DPP 
Negatives controls CCZ - Araucária - PR 73 Culture, ELISA, TR-DPP 
* Clinical signs: the main clinical features observed for this classification were alopecia, peeling dry skin, brittle skin, 664 
nodules on the skin, ulcers, weakness, low weight, and ocular lesions.  665 
 666 
 667 
Table 2. Lbk39 test sensitivity and specificity for the sample of 56 positive canine sample cultures, 668 






Lbk39 Estimate CI min CI max,  Estimate CI min CI max 
Clinical signs 100 90.3 100 98.7 92.8 100 




Table 3.  Comparision between Lbk39 antigen and other methods (TR DPP®, iELISA and culture in 673 
artificial media) analysing 78 positive dogs and 75 negative controls. 674 
Test Sensitivity (%) Specificity (%) 
 Estimate CI min CI max Estimate CI min CI max 
ELISA-Lbk39 antigen 100 95.3 100 96.1 89 99.2 
TR DPP 93.8 90 96.3 97.2 95.7 98.2 
ELISA crude extract 98.1 95.5 99.2 86.9 84.5 89 
Culture 77 69.8 82.9 100 - - 
 675 
  676 
Table 4.  Comparision between Lbk39 antigen and TR DPP for the sample of 78 positive controls, according 677 
to clinical classification (with or without clinical signs). 678 
Test Sensitivity (%) Specificity (%) 
 Estimate CI min CI max Estimate CI min CI max 
Lbk39 ELISA       
         Clinical signs 98 89.6 100 98.7 92.9 100 
         No clinical signs 100 86.3 100 96.1 88.9 99.2 
TR-DPP test       
         Clinical signs 98 90 100 100 95 100 




Figure 1. SDS PAGE of induction and purification of LKb39. 682 
 683 
 684 





Figure 3. Comparison of ELISA reactivity of canine sera against Lbk39 recombinant proteins in true 690 
positive cultures. AUC: accuracy. 691 
 692 
 693 
Figure 4. Box and whisker plot comparisons of absorbance distributions in different groups of dog sera. a) 694 
Analysis of all samples. b) Analysis of the subset of ELISA positives that also had a positive culture. The 695 




Figure 5. Analyses of cross-reaction with Lbk39 against Toxoplasma gondii compared with negative 700 
controls and dogs with and without clinical signs. 701 
 702 
